Drug intelligence / Profile preview

UCART019

Development stage: Phase 2
Lead developer: Servier
Modality: Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

UCART019 is an allogeneic, gene-disrupted, CD19-specific chimeric antigen receptor (CAR)-T cell therapy. It is engineered by combining lentiviral delivery of the CAR with CRISPR RNA electroporation to simultaneously disrupt endogenous T-cell receptor (TCR) and Beta-2 microglobulin (B2M) genes. This engineering aims to prevent graft-versus-host disease (GVHD) and minimize immunogenicity, allowing the use of T cells from healthy unrelated donors. UCART019 is being developed for the treatment of relapsed or refractory CD19+ B-cell leukemias and lymphomas.

Other names: Universal CD19-specific CAR-T cell

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on UCART019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UCART019.

Explore the full profile